Microbot Medical Inc. announced the first closing of its exercise of certain outstanding preferred investment options to purchase up to 13,989,115 shares of common stock. The closing is expected to occur in two tranches, with the first closing resulting in gross proceeds of approximately $25.2 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The Company intends to use the net proceeds for development, commercialization, regulatory activities, potential acquisitions, and working capital. The new short-term series J preferred investment options were offered in a private placement.

Microbot Medical Inc. is a medical device company focused on transforming endovascular procedures through advanced robotic technology. The company’s LIBERTY® Endovascular Robotic System is a single-use, remotely operated robotic solution designed for precision and efficiency. Forward-looking statements involve risks and uncertainties, including completion of the second closing of the offering, market conditions, regulatory approvals, and geopolitical conditions. For more information, visit www.microbotmedical.com. Contact [email protected] or [email protected] for inquiries.

Read more at GlobeNewswire: Microbot Medical Announces First Closing of Exercise of